AstraZeneca announces that detailed results from a Phase III trial showed that Enhertu (trastuzumab deruxtecan) significantly improved progression-free survival (PFS) compared with standard chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer.

Enhertu reduced the risk of disease progression or death by 38%, and the median PFS was 13.2 months versus 8.1 months for chemotherapy.

Results will be presented at the ASCO 2024 Annual Meeting. Enhertu is being developed by Daiichi Sankyo and AstraZeneca.

Copyright (c) 2024 CercleFinance.com. All rights reserved.